Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SAM-531
SAM-531 and gemfibrozil · 8 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SAM-531 | DRUG | - |
| placebo | OTHER | - |
Inclusion Criteria 1. Signed and dated written informed consent obtained from the subject or the subject's legally authorized representative (LAR) or next of kin (if applicable), in accordance with the local regulations. The subject's caregiver must also consent to participate in the study. 2. Diag...
Top 20 of 30 competitors
SAM-531 is an investigational small molecule that was studied as a treatment for Alzheimer Disease. It was developed by Pfizer and reached Phase 2 clinical development. All eight of its registered trials have been completed, and no trials are currently active. It is not described as an approved therapy for Alzheimer Disease.
SAM-531 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical program evaluating the compound in Alzheimer Disease, including Phase 1 pharmacokinetic and drug interaction studies and a Phase 2 study in patients with mild to moderate disease.
SAM-531 reached Phase 2 clinical development for Alzheimer Disease. Eight trials have been registered in total, all of which are completed, and none are currently active. The program includes Phase 1 studies in healthy volunteers and a Phase 2 study in patients with mild to moderate Alzheimer Disease.
SAM-531 has been studied in eight completed trials, including NCT00906191, a Phase 1 absorption, metabolism and elimination study in the Netherlands; NCT00745576, a Phase 1 verapamil interaction study in France; NCT00726115, a Phase 1 single and multiple dose study in France; and NCT00481520, a Phase 2 study in mild to moderate Alzheimer Disease in the United States.